The Iterative Development of Medicines Through the European Medicine Agency's Adaptive Pathway Approach

  • Nicotera G
  • Sferrazza G
  • Serafino A
  • et al.
N/ACitations
Citations of this article
12Readers
Mendeley users who have this article in their library.

Abstract

The development of novel regulatory tools such as adaptive clinical trial design and utilization of real-world evidence are topics of high interest. Recently, the European Medicines Agency (EMA) introduced the Adaptive Pathways (AP) that represents an innovative tool in healthcare systems allowing the early dialogue with multiple stakeholders on promising and innovative medicinal products in areas with an high unmet medical need. The innovative aspect in the AP is the early involvement of several stakeholders such as pharmaceutical industry, the Academia, Health Technology Assessment (HTA) bodies and patient representatives bringing their real experience with the disease and their expectations about the treatment. AP is not a new licensing tool but an opportunity for a very early discussions, before starting the phase II studies, among all stakeholders, including regulators, companies, HTA bodies, and patient representatives on a new potential medicine in areas of high unmet medical need. The aim of this paper is to describe the evolution of the AP approach from the beginning of the pilot project to date, highlighting major advances and achievement at European level.

Cite

CITATION STYLE

APA

Nicotera, G., Sferrazza, G., Serafino, A., & Pierimarchi, P. (2019). The Iterative Development of Medicines Through the European Medicine Agency’s Adaptive Pathway Approach. Frontiers in Medicine, 6. https://doi.org/10.3389/fmed.2019.00148

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free